Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 9/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12642197 | 0.88 | GCGR (0.41) | MAPTGCGRTLR8 | |
| SCHEMBL20036835 | 0.84 | GPR84 (0.36) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL12642230 | 0.83 | GCGR (0.49) | MAPTGCGRTLR8CNR1 | |
| SCHEMBL12642413 | 0.80 | GCGR (0.50) | MAPTGCGRTLR8CNR1 | |
| SCHEMBL16256937 | 0.79 | BCHE (0.36) | KDM4EALDH1A1 | |
| SCHEMBL12642495 | 0.79 | CNR2 (0.42) | MAPTGCGRTLR8 | |
| SCHEMBL30498972 | 0.79 | GPR84 (0.36) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL12642198 | 0.77 | MAPT (0.39) | MAPTGCGRTLR8KDM4EALDH1A1 | |
| SCHEMBL12642409 | 0.77 | GCGR (0.51) | MAPTGCGRKDM4EALDH1A1GAA | |
| SCHEMBL12642414 | 0.77 | CNR2 (0.45) | MAPTTLR8KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034688-A1 | OPTICALLY ACTIVE DIBENZAZEPINE DERIVATIVES | NIPPON SODA CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034688-A1 | OPTICALLY ACTIVE DIBENZAZEPINE DERIVATIVES | DRD1, DRD4, DRD2 | MAPT 3014/4885GCGR 2645/4885TLR8 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.